Two Sigma Investments LP Invests $391,000 in CureVac (NASDAQ:CVAC)

Two Sigma Investments LP bought a new position in CureVac (NASDAQ:CVAC) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 114,685 shares of the company’s stock, valued at approximately $391,000. Two Sigma Investments LP owned approximately 0.05% of CureVac as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also added to or reduced their stakes in CVAC. Jump Financial LLC bought a new stake in CureVac in the fourth quarter worth approximately $55,000. D. E. Shaw & Co. Inc. bought a new stake in CureVac in the fourth quarter worth approximately $66,000. XTX Topco Ltd increased its holdings in CureVac by 90.2% in the fourth quarter. XTX Topco Ltd now owns 24,365 shares of the company’s stock worth $83,000 after purchasing an additional 11,553 shares in the last quarter. Barclays PLC increased its holdings in CureVac by 51.8% in the fourth quarter. Barclays PLC now owns 34,836 shares of the company’s stock worth $118,000 after purchasing an additional 11,890 shares in the last quarter. Finally, Signaturefd LLC increased its holdings in CureVac by 29.2% in the fourth quarter. Signaturefd LLC now owns 36,140 shares of the company’s stock worth $123,000 after purchasing an additional 8,170 shares in the last quarter. 17.26% of the stock is currently owned by institutional investors.

CureVac Price Performance

Shares of CVAC opened at $4.27 on Wednesday. CureVac has a 12-month low of $2.37 and a 12-month high of $5.00. The business’s fifty day moving average is $3.62 and its 200 day moving average is $3.44. The company has a quick ratio of 6.19, a current ratio of 6.20 and a debt-to-equity ratio of 0.05. The stock has a market cap of $957.92 million, a P/E ratio of 7.76 and a beta of 2.49.

CureVac (NASDAQ:CVAC) last issued its earnings results on Thursday, May 22nd. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.08). CureVac had a return on equity of 21.98% and a net margin of 20.72%. The firm had revenue of $0.94 million during the quarter, compared to the consensus estimate of $4.27 million. Sell-side analysts anticipate that CureVac will post 0.72 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have weighed in on CVAC. UBS Group lowered their target price on CureVac from $13.00 to $12.00 and set a “buy” rating for the company in a report on Wednesday, April 30th. JMP Securities reaffirmed a “market outperform” rating and set a $10.00 target price on shares of CureVac in a research report on Wednesday, May 28th.

CureVac Profile

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.